TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03763721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative optical coherence tomography (iOCT)
Description: The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraoperative optical coherence tomography (iOCT)
Description: The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery.
Study: NCT01829386

Intervention type: OTHER
Intervention: MRI scans with non heme iron levels
Description: MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research.
Study: NCT01034943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixation
Description: Operation with external fixation and optional addition of k-wire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar plate
Description: Operation with a Synthes volar two column plate (TCP)
Study: NCT02311972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips InnerSense Esophageal Temperature Sensor/Feeding Tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care feeding tube
Study: NCT04333589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
Study: NCT00227682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ascorbic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study: NCT01596751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
Study: NCT03359460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01460290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
Study: NCT00978237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV
Description: one pill QD VO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: 2 pills QD VO
Study: NCT02897622

Intervention type: OTHER
Group type: OTHER
Intervention: Case management
Description: Case management by Eira unit
Study: NCT01365637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension either twice or thrice daily
Study: NCT01754818

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01345318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04236921
Description: Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04236921
Description: Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
Study: NCT04715776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown seaweed
Description: Uptake of 1650 mg brown seaweed product twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown seaweed
Description: Uptake of 1650 mg brown seaweed product twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Uptake of 1650 mg placebo twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Uptake of 1650 mg placebo twice daily
Study: NCT01577693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: novel dutasteride

Intervention type: DRUG
Group type: OTHER
Intervention: dutasteride
Description: dutasteride soft gel capsule
Study: NCT01730560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month).
Study: NCT00518882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg once daily for s.c. (under the skin) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 10 mcg twice daily for s.c. (under the skin) injection.
Study: NCT01128582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rozerem (ramelteon)
Description: dosage= take 1 tablet(8 MG) 20 min. before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
Study: NCT01581775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium ER Tablets, 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium ER Tablets, 500 mg
Study: NCT04010695

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SD Biosensor G6PD Analyzer
Description: The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
Study: NCT01365637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension either twice or thrice daily
Study: NCT00405951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate 250 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT02925195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: cholecalciferol (vitamin D3) 2000 IU capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01050569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: 21 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VLNC Cigarette
Description: Cigarette where the tobacco contains \<0.1 mg of nicotine yield.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC Cigarette Plus Nicotine Patch
Description: 21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
Study: NCT02118077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study: NCT00810680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
Study: NCT03587168

Intervention type: OTHER
Intervention: the timed 360° turn test
Description: Turning ability is assessed by using the timed 360° turn test.

Intervention type: OTHER
Intervention: the timed 360° turn test
Description: Turning ability is assessed by using the timed 360° turn test.

Intervention type: OTHER
Intervention: Berg Balance Scale
Description: Functional balance is assessed by using the Berg Balance Scale.

Intervention type: OTHER
Intervention: Four Square Step Test
Description: The Four Square Step Test measures dynamic balance.

Intervention type: OTHER
Intervention: Functional Reach Test
Description: The Functional Reach Test assesses limits of stability.

Intervention type: OTHER
Intervention: Trunk Impairment Scale
Description: Trunk performance is assessed by using the trunk impairment scale.

Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: Functional mobility is assessed by using the timed up and go test.

Intervention type: OTHER
Intervention: Hoehn and Yahr Scale
Description: Disease stage is assessed by the Hoehn and Yahr Scale.

Intervention type: OTHER
Intervention: Unified Parkinson's Disease Rating Scale
Description: The Unified Parkinson's Disease Rating Scale assesses disease severity.
Study: NCT00571818

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: test done over 2 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: test done over 2 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: test done over 2 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: test done over 2 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV Glucose Tolerance Test
Description: Done over 4 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV Glucose Tolerance Test
Description: Done over 4 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV Glucose Tolerance Test
Description: Done over 4 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV Glucose Tolerance Test
Description: Done over 4 hours
Study: NCT01491399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™
Description: Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™
Description: Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
Study: NCT04220632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
Study: NCT01818050

Intervention type: OTHER
Group type: OTHER
Intervention: Liver Function Tests
Description: LFTs will be checked periodically after Wing stent placement to evaluate stent patency
Study: NCT01897181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aids
Description: Using hearing aids for 12 months
Study: NCT01165593

Intervention type: OTHER
Intervention: There is no intervention that is a part of this study.
Description: There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
Study: NCT01426607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMO

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AMO
Study: NCT03656120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2mg group
Description: Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg group
Description: Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control group
Description: Participants only take placebos for 12 weeks during the research.
Study: NCT03081286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Liposuction
Description: Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat graft
Description: The harvested lipoaspirate is injected at the site of pain.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham graft (saline injection)
Description: Saline will be injected at the site of pain instead of fat
Study: NCT03280017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline infusion
Study: NCT02762006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is a CTLA-4 monoclonal antibody.
Study: NCT00855465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tid orally for 16 weeks
Study: NCT03030248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Oral Capsule
Description: We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
Study: NCT04435002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure technics applied to (Liv- 4 , Ht-7 Bilateral, Liv-3 Bilateral, Anmian Bilateral, Yin-Tang unilateral ve Sp-6 Bilateral)
Study: NCT03432988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Solution-Focused
Description: Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
Study: NCT01713179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)
Study: NCT01401387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of start treatment with pancreatic enzymes
Description: Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of start treatment with pancreatic enzymes
Description: Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
Study: NCT02660645

Intervention type: DRUG
Intervention: Hexaminolevulinate hydrochloride (HCL)
Description: Instillation in bladder

Intervention type: DEVICE
Intervention: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Description: Cystoscopy procedure
Study: NCT01610479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-114 + S-1
Study: NCT02817724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BENECA System
Description: BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
Study: NCT02537379

Intervention type: DRUG
Intervention: SOF
Description: SOF 400 mg tablets administered orally once daily
Study: NCT04010695

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pointe Scientific Test Kit
Description: The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HemoCue System
Description: The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
Study: NCT02817724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BENECA System
Description: BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised-occupational therapy program
Description: It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.